US71375U1016 - Common Stock
Perficient Inc. is considering a potential sale, people familiar with the matter said.
Perficient's Q4 results fall short as non-GAAP EPS and revenue miss estimates, while net income and adjusted earnings per share decline.
It's time to sell these three declining stocks which have disappointed investors all year with their plummeting share values.
Perficient reports Q3 results: Non-GAAP EPS in-line at $0.92, beats revenue estimates by $1.19M with $223.2M.
Perficient announces acquisition of SMEDIX, a healthcare software engineering firm, to enhance capabilities and expand product offerings in the industry.